A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.

被引：0
|
作者：
Bjerregaard, Jon Kroll
Ladekarl, Morten
Jensen, Helle Anita
Vestermark, Lene Weber
Farr, Katherina Podlekareva
Pfeiffer, Per
机构：
[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark
[2] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
[3] Odense Univ Hosp, DK-5000 Odense, Denmark
[4] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e15238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15238
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Caputo, G.
    Novello, G.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 781 - 786
  • [22] A Randomized Multicenter Trial of Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx) in the treatment of patients with advanced pancreatic cancer
    Golf, Alexander
    Hoehler, Thomas
    Seipelt, Gernot
    Mahlberg, Rolf
    Wein, Axel
    Hichhaus, Andreas
    Schmid, Birgit
    Boeck, Hans-Peter
    Hinke, Axel
    Boeck, Stefan
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2004, 15 : 243 - 243
  • [23] Randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with advanced or recurrent colorectal cancer.
    Zang, Dae Young
    Chung, Ik-Joo
    Oh, Ho-Suk
    Park, Keon Uk
    Lee, Kyung Hee
    Han, Boram
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [24] A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer
    Maroun, Jean
    Marginean, Horia
    Jonker, Derek
    Cripps, Christine
    Goel, Rakesh
    Asmis, Timothy
    Goodwin, Rachel
    Chiritescu, Gabriela
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E257 - E268
  • [25] A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.
    Omuro, Y.
    Ikari, T.
    Ishii, H.
    Ozaka, M.
    Suyama, M.
    Matsumura, Y.
    Itoi, T.
    Egawa, N.
    Yano, S.
    Hanada, K.
    Kimura, Y.
    Ukita, T.
    Ishida, Y.
    Tani, M.
    Ohoka, S.
    Hirose, Y.
    Hijioka, S.
    Watanabe, R.
    Ikeda, T.
    Nakajima, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
    Saltz, LB
    Lenz, HJ
    Hochster, H
    Wadler, S
    Hoff, P
    Kemeny, N
    Hollywood, E
    Gonen, M
    Wetherbee, S
    Chen, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 248S - 248S
  • [27] Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
    Cunningham, David
    Chau, Ian
    Stocken, Deborah D.
    Valle, Juan W.
    Smith, David
    Steward, William
    Harper, Peter G.
    Dunn, Janet
    Tudur-Smith, Catrin
    West, Julia
    Falk, Stephen
    Crellin, Adrian
    Adab, Fawzi
    Thompson, Joyce
    Leonard, Pauline
    Ostrowski, Joe
    Eatock, Martin
    Scheithauer, Werner
    Herrmann, Richard
    Neoptolemos, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) : 5513 - 5518
  • [28] Phase two clinical trial of combination oxaliplatin, irinotecan, and cetuximab for patients with locally advanced or metastatic pancreatic cancer.
    Abdou, Yara
    Friend, Sarah Cooke
    Patt, Yehuda Z.
    Gan, Christine
    Lee, Fa-Chyi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial
    Kim, Se Hyun
    Shin, Sang Joon
    Kim, Sun Young
    Lee, Se Hoon
    Park, Young Suk
    Park, Se Hoon
    Lee, Kyung Hee
    Kim, Tae Won
    Hong, Yong Sang
    Ahn, Joong Bae
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 91 - 97
  • [30] Combining Capecitabine, Oxaliplatin and Gemcitabine (XELOXGEM) for Colorectal Carcinoma Patients Pretreated With Irinotecan - a Multicenter Phase I/II Trial
    Kim, S. H.
    Shin, S. J.
    Kim, S. Y.
    Lee, S. H.
    Park, Y. S.
    Lee, K. H.
    Kim, T. W.
    Hong, Y. S.
    Ahn, J. B.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S425 - S425
12345